8-K: InMed Pharmaceuticals Announces Oral Formulation of INM-901 for Alzheimer's Treatment

InMed Pharmaceuticals has confirmed that its drug candidate INM-901 can be administered orally, achieving similar brain drug concentrations as an injection, which is a significant step in its development for Alzheimer's disease.

Summary

• InMed Pharmaceuticals has announced that its drug candidate, INM-901, can be effectively administered orally for the treatment of Alzheimer's disease.
• Preclinical studies show that the oral formulation of INM-901 achieves similar drug concentration levels in the brain as an intraperitoneal (IP) injection.
• This oral delivery method could reduce treatment costs compared to intravenous delivery of current antibody therapies.
• INM-901 is a small molecule that can be absorbed in the gastrointestinal tract, enter the bloodstream, and cross the blood-brain barrier.
• Current Alzheimer's treatments using large molecules have side effects like inflammation and bleeding in the brain, requiring frequent monitoring.
• InMed aims to provide an effective, orally delivered, disease-modifying treatment for Alzheimer's disease.
• The company is conducting further studies, including drug metabolism, dose ranging, and pharmacokinetic studies, to support an IND submission.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical results for INM-901, highlighting its potential as an oral treatment for Alzheimer's. The focus on cost-effectiveness and patient convenience is also encouraging. However, it is still in the early stages of development.

Positives

• The oral formulation of INM-901 offers a more convenient and potentially cost-effective treatment option compared to current intravenous therapies.
• INM-901's ability to cross the blood-brain barrier effectively is a significant advantage for treating Alzheimer's disease.
• The small molecule nature of INM-901 may reduce the side effects associated with current large molecule treatments.
• Preclinical studies have shown that INM-901 has neuroprotective effects, can extend neurite length, and reduce neuroinflammation.

Negatives

• The document does not mention any negative aspects of the drug or the company.

Risks

• The development of INM-901 is still in preclinical stages, and further studies are needed to support an IND submission.
• There are risks and uncertainties associated with the development of new drugs, and actual results may differ from forward-looking statements.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Future Outlook

The company is conducting further studies, including chemistry, manufacturing, and controls (CMC), drug metabolism, dose ranging, and pharmacokinetic studies to support an IND submission for INM-901.

Management Comments

• Michael Woudenberg, InMed's Chief Operating Officer, stated that they are excited by the data confirming that INM-901 can be delivered across the blood brain barrier as an oral formulation.
• Management believes the oral formulation provides significant advantages for further development of this compound in the treatment of Alzheimer's.

Industry Context

This announcement is significant as it addresses the challenges of delivering drugs to the brain for neurodegenerative diseases, particularly Alzheimer's. The development of an oral formulation for a small molecule drug candidate like INM-901 could be a major advancement compared to current antibody-based treatments that require intravenous administration.

Comparison to Industry Standards

• Current Alzheimer's treatments, such as those using large molecule antibodies from companies like Biogen (Aduhelm) and Eisai (Leqembi), require intravenous or subcutaneous administration, which are less convenient and more costly than oral delivery.
• The development of an oral small molecule drug like INM-901 is a departure from the current trend of antibody-based therapies, potentially offering a more accessible and patient-friendly treatment option.
• The ability of INM-901 to achieve similar brain drug concentrations via oral administration as IP injection is a significant advantage, as oral delivery is generally preferred for patient convenience and cost-effectiveness.

Stakeholder Impact

• Shareholders may view this announcement positively due to the potential for a more effective and accessible treatment for Alzheimer's disease.
• Patients with Alzheimer's disease and their families could benefit from a more convenient and potentially less costly oral treatment option.
• The company's employees may be motivated by the progress in developing a promising drug candidate.

Next Steps

• The company will conduct further chemistry, manufacturing, and controls (CMC) studies for both the drug substance and the drug product formulation.
• Drug metabolism studies, dose ranging studies, and pharmacokinetic studies will be performed to support an IND submission.

Key Dates

Keywords

INM-901, Alzheimer's disease, oral formulation, small molecule, neurodegenerative diseases, blood-brain barrier, drug delivery, preclinical studies, neuroinflammation, neuroprotective